Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder

Major depressive disorder (MMD) is a leading cause of disability worldwide. Approximately one-third of patients with MDD fail to achieve response or remission leading to treatment-resistant depression (TRD). One of the psychopharmacological strategies to overcome TRD is using a combination of an ant...

Full description

Bibliographic Details
Main Authors: Manal E. Alkahtani, Alhassan H. Aodah, Omar A. Abu Asab, Abdul W. Basit, Mine Orlu, Essam A. Tawfik
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/13/6/891
_version_ 1797530011989704704
author Manal E. Alkahtani
Alhassan H. Aodah
Omar A. Abu Asab
Abdul W. Basit
Mine Orlu
Essam A. Tawfik
author_facet Manal E. Alkahtani
Alhassan H. Aodah
Omar A. Abu Asab
Abdul W. Basit
Mine Orlu
Essam A. Tawfik
author_sort Manal E. Alkahtani
collection DOAJ
description Major depressive disorder (MMD) is a leading cause of disability worldwide. Approximately one-third of patients with MDD fail to achieve response or remission leading to treatment-resistant depression (TRD). One of the psychopharmacological strategies to overcome TRD is using a combination of an antipsychotic as an augmenting agent with selective serotonin reuptake inhibitors (SSRIs). Among which, an atypical antipsychotic, quetiapine (QUE), and an SSRI, escitalopram (ESC), were formulated as a fixed-dose combination as a fast-dissolving film by coaxial electrospinning. The resultant fiber’s morphology was studied. SEM images showed that the drug-loaded fibers were smooth, un-beaded, and non-porous with a fiber diameter of 0.9 ± 0.1 µm, while the TEM images illustrated the distinctive layers of the core and shell, confirming the successful preparation of these fibers. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) studies confirmed that both drugs were amorphously distributed within the drug-loaded fibers. The drug-loaded fibers exhibited a disintegration time of 2 s, which accelerated the release of both drugs (50% after 5 min) making it an attractive formulation for oral mucosal delivery. The ex vivo permeability study demonstrated that QUE was permeated through the buccal membrane, but not ESC that might be hindered by the buccal epithelium and the intercellular lipids. Overall, the developed coaxial fibers could be a potential buccal dosage form that could be attributed to higher acceptability and adherence among vulnerable patients, particularly mentally ill patients.
first_indexed 2024-03-10T10:22:50Z
format Article
id doaj.art-cd2558eee8624a99a14e7aa1b547df35
institution Directory Open Access Journal
issn 1999-4923
language English
last_indexed 2024-03-10T10:22:50Z
publishDate 2021-06-01
publisher MDPI AG
record_format Article
series Pharmaceutics
spelling doaj.art-cd2558eee8624a99a14e7aa1b547df352023-11-22T00:18:14ZengMDPI AGPharmaceutics1999-49232021-06-0113689110.3390/pharmaceutics13060891Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive DisorderManal E. Alkahtani0Alhassan H. Aodah1Omar A. Abu Asab2Abdul W. Basit3Mine Orlu4Essam A. Tawfik5UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UKNational Center for Pharmaceutical Technology, Life Science & Environment Research Institute, King Abdulaziz City for Science and Technology, 6086, Riyadh 11442, Saudi ArabiaNational Center for Pharmaceutical Technology, Life Science & Environment Research Institute, King Abdulaziz City for Science and Technology, 6086, Riyadh 11442, Saudi ArabiaUCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UKUCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UKNational Center for Pharmaceutical Technology, Life Science & Environment Research Institute, King Abdulaziz City for Science and Technology, 6086, Riyadh 11442, Saudi ArabiaMajor depressive disorder (MMD) is a leading cause of disability worldwide. Approximately one-third of patients with MDD fail to achieve response or remission leading to treatment-resistant depression (TRD). One of the psychopharmacological strategies to overcome TRD is using a combination of an antipsychotic as an augmenting agent with selective serotonin reuptake inhibitors (SSRIs). Among which, an atypical antipsychotic, quetiapine (QUE), and an SSRI, escitalopram (ESC), were formulated as a fixed-dose combination as a fast-dissolving film by coaxial electrospinning. The resultant fiber’s morphology was studied. SEM images showed that the drug-loaded fibers were smooth, un-beaded, and non-porous with a fiber diameter of 0.9 ± 0.1 µm, while the TEM images illustrated the distinctive layers of the core and shell, confirming the successful preparation of these fibers. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) studies confirmed that both drugs were amorphously distributed within the drug-loaded fibers. The drug-loaded fibers exhibited a disintegration time of 2 s, which accelerated the release of both drugs (50% after 5 min) making it an attractive formulation for oral mucosal delivery. The ex vivo permeability study demonstrated that QUE was permeated through the buccal membrane, but not ESC that might be hindered by the buccal epithelium and the intercellular lipids. Overall, the developed coaxial fibers could be a potential buccal dosage form that could be attributed to higher acceptability and adherence among vulnerable patients, particularly mentally ill patients.https://www.mdpi.com/1999-4923/13/6/891major depressive disordertreatment-resistant depressioncoaxial fiberselectrospinningfast-dissolving filmsescitalopram
spellingShingle Manal E. Alkahtani
Alhassan H. Aodah
Omar A. Abu Asab
Abdul W. Basit
Mine Orlu
Essam A. Tawfik
Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder
Pharmaceutics
major depressive disorder
treatment-resistant depression
coaxial fibers
electrospinning
fast-dissolving films
escitalopram
title Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder
title_full Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder
title_fullStr Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder
title_full_unstemmed Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder
title_short Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder
title_sort fabrication and characterization of fast dissolving films containing escitalopram quetiapine for the treatment of major depressive disorder
topic major depressive disorder
treatment-resistant depression
coaxial fibers
electrospinning
fast-dissolving films
escitalopram
url https://www.mdpi.com/1999-4923/13/6/891
work_keys_str_mv AT manalealkahtani fabricationandcharacterizationoffastdissolvingfilmscontainingescitalopramquetiapineforthetreatmentofmajordepressivedisorder
AT alhassanhaodah fabricationandcharacterizationoffastdissolvingfilmscontainingescitalopramquetiapineforthetreatmentofmajordepressivedisorder
AT omaraabuasab fabricationandcharacterizationoffastdissolvingfilmscontainingescitalopramquetiapineforthetreatmentofmajordepressivedisorder
AT abdulwbasit fabricationandcharacterizationoffastdissolvingfilmscontainingescitalopramquetiapineforthetreatmentofmajordepressivedisorder
AT mineorlu fabricationandcharacterizationoffastdissolvingfilmscontainingescitalopramquetiapineforthetreatmentofmajordepressivedisorder
AT essamatawfik fabricationandcharacterizationoffastdissolvingfilmscontainingescitalopramquetiapineforthetreatmentofmajordepressivedisorder